nodes	percent_of_prediction	percent_of_DWPC	metapath
Ifosfamide—Alkylating Activity—Dacarbazine—muscle cancer	0.488	1	CiPCiCtD
Ifosfamide—hematologic cancer—muscle cancer	0.176	0.456	CtDrD
Ifosfamide—testicular cancer—muscle cancer	0.107	0.278	CtDrD
Ifosfamide—germ cell cancer—muscle cancer	0.102	0.266	CtDrD
Ifosfamide—PTGS1—Etoposide—muscle cancer	0.0124	0.174	CbGbCtD
Ifosfamide—CYP3A7—Vincristine—muscle cancer	0.0108	0.152	CbGbCtD
Ifosfamide—CYP3A7-CYP3A51P—Vincristine—muscle cancer	0.0108	0.152	CbGbCtD
Ifosfamide—CYP3A5—Vincristine—muscle cancer	0.00811	0.114	CbGbCtD
Ifosfamide—CYP3A5—Etoposide—muscle cancer	0.00743	0.104	CbGbCtD
Ifosfamide—CYP2C8—Etoposide—muscle cancer	0.00715	0.1	CbGbCtD
Ifosfamide—CYP2B6—Doxorubicin—muscle cancer	0.00643	0.0904	CbGbCtD
Ifosfamide—CYP3A4—Vincristine—muscle cancer	0.00316	0.0444	CbGbCtD
Ifosfamide—CYP3A4—Etoposide—muscle cancer	0.0029	0.0407	CbGbCtD
Ifosfamide—CYP3A4—Doxorubicin—muscle cancer	0.00198	0.0278	CbGbCtD
Ifosfamide—Fatigue—Dactinomycin—muscle cancer	4.96e-05	0.000888	CcSEcCtD
Ifosfamide—Pain—Dactinomycin—muscle cancer	4.92e-05	0.00088	CcSEcCtD
Ifosfamide—Anorexia—Vincristine—muscle cancer	4.9e-05	0.000877	CcSEcCtD
Ifosfamide—Hepatic failure—Doxorubicin—muscle cancer	4.89e-05	0.000875	CcSEcCtD
Ifosfamide—Hypotension—Vincristine—muscle cancer	4.8e-05	0.00086	CcSEcCtD
Ifosfamide—Renal failure acute—Doxorubicin—muscle cancer	4.76e-05	0.000852	CcSEcCtD
Ifosfamide—Feeling abnormal—Dactinomycin—muscle cancer	4.74e-05	0.000848	CcSEcCtD
Ifosfamide—Ill-defined disorder—Etoposide—muscle cancer	4.73e-05	0.000847	CcSEcCtD
Ifosfamide—Anaemia—Etoposide—muscle cancer	4.71e-05	0.000844	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Dactinomycin—muscle cancer	4.7e-05	0.000842	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Vincristine—muscle cancer	4.68e-05	0.000838	CcSEcCtD
Ifosfamide—Renal impairment—Doxorubicin—muscle cancer	4.62e-05	0.000826	CcSEcCtD
Ifosfamide—Paraesthesia—Vincristine—muscle cancer	4.61e-05	0.000826	CcSEcCtD
Ifosfamide—Malaise—Etoposide—muscle cancer	4.6e-05	0.000823	CcSEcCtD
Ifosfamide—Breast disorder—Methotrexate—muscle cancer	4.58e-05	0.000821	CcSEcCtD
Ifosfamide—Vertigo—Etoposide—muscle cancer	4.58e-05	0.00082	CcSEcCtD
Ifosfamide—Toxic epidermal necrolysis—Methotrexate—muscle cancer	4.57e-05	0.000818	CcSEcCtD
Ifosfamide—Leukopenia—Etoposide—muscle cancer	4.56e-05	0.000817	CcSEcCtD
Ifosfamide—Body temperature increased—Dactinomycin—muscle cancer	4.55e-05	0.000814	CcSEcCtD
Ifosfamide—Abdominal pain—Dactinomycin—muscle cancer	4.55e-05	0.000814	CcSEcCtD
Ifosfamide—Cardiac failure—Doxorubicin—muscle cancer	4.5e-05	0.000806	CcSEcCtD
Ifosfamide—Decreased appetite—Vincristine—muscle cancer	4.47e-05	0.0008	CcSEcCtD
Ifosfamide—Cough—Etoposide—muscle cancer	4.45e-05	0.000797	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Vincristine—muscle cancer	4.44e-05	0.000794	CcSEcCtD
Ifosfamide—Fatigue—Vincristine—muscle cancer	4.43e-05	0.000793	CcSEcCtD
Ifosfamide—Convulsion—Etoposide—muscle cancer	4.42e-05	0.000791	CcSEcCtD
Ifosfamide—Hypertension—Etoposide—muscle cancer	4.4e-05	0.000788	CcSEcCtD
Ifosfamide—Pain—Vincristine—muscle cancer	4.39e-05	0.000787	CcSEcCtD
Ifosfamide—Constipation—Vincristine—muscle cancer	4.39e-05	0.000787	CcSEcCtD
Ifosfamide—Pain in extremity—Doxorubicin—muscle cancer	4.39e-05	0.000786	CcSEcCtD
Ifosfamide—Osteoarthritis—Doxorubicin—muscle cancer	4.39e-05	0.000786	CcSEcCtD
Ifosfamide—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	4.39e-05	0.000786	CcSEcCtD
Ifosfamide—Chest pain—Etoposide—muscle cancer	4.34e-05	0.000777	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	4.31e-05	0.000772	CcSEcCtD
Ifosfamide—Pancreatitis—Methotrexate—muscle cancer	4.3e-05	0.000769	CcSEcCtD
Ifosfamide—Discomfort—Etoposide—muscle cancer	4.29e-05	0.000768	CcSEcCtD
Ifosfamide—Hypersensitivity—Dactinomycin—muscle cancer	4.24e-05	0.000759	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Vincristine—muscle cancer	4.2e-05	0.000752	CcSEcCtD
Ifosfamide—Confusional state—Etoposide—muscle cancer	4.2e-05	0.000751	CcSEcCtD
Ifosfamide—Cardiac arrest—Doxorubicin—muscle cancer	4.18e-05	0.000748	CcSEcCtD
Ifosfamide—Pancytopenia—Methotrexate—muscle cancer	4.16e-05	0.000745	CcSEcCtD
Ifosfamide—Anaphylactic shock—Etoposide—muscle cancer	4.16e-05	0.000745	CcSEcCtD
Ifosfamide—Infection—Etoposide—muscle cancer	4.13e-05	0.00074	CcSEcCtD
Ifosfamide—Asthenia—Dactinomycin—muscle cancer	4.13e-05	0.000739	CcSEcCtD
Ifosfamide—Blood creatinine increased—Doxorubicin—muscle cancer	4.11e-05	0.000737	CcSEcCtD
Ifosfamide—Dysuria—Methotrexate—muscle cancer	4.1e-05	0.000734	CcSEcCtD
Ifosfamide—Thrombocytopenia—Etoposide—muscle cancer	4.08e-05	0.00073	CcSEcCtD
Ifosfamide—Abdominal pain—Vincristine—muscle cancer	4.06e-05	0.000727	CcSEcCtD
Ifosfamide—Body temperature increased—Vincristine—muscle cancer	4.06e-05	0.000727	CcSEcCtD
Ifosfamide—Skin disorder—Etoposide—muscle cancer	4.04e-05	0.000724	CcSEcCtD
Ifosfamide—Hyperhidrosis—Etoposide—muscle cancer	4.02e-05	0.00072	CcSEcCtD
Ifosfamide—Hypokalaemia—Doxorubicin—muscle cancer	4e-05	0.000716	CcSEcCtD
Ifosfamide—Breast disorder—Doxorubicin—muscle cancer	3.97e-05	0.000711	CcSEcCtD
Ifosfamide—Anorexia—Etoposide—muscle cancer	3.97e-05	0.00071	CcSEcCtD
Ifosfamide—Toxic epidermal necrolysis—Doxorubicin—muscle cancer	3.96e-05	0.000708	CcSEcCtD
Ifosfamide—Diarrhoea—Dactinomycin—muscle cancer	3.93e-05	0.000704	CcSEcCtD
Ifosfamide—Pneumonia—Methotrexate—muscle cancer	3.93e-05	0.000704	CcSEcCtD
Ifosfamide—Infestation NOS—Methotrexate—muscle cancer	3.91e-05	0.0007	CcSEcCtD
Ifosfamide—Infestation—Methotrexate—muscle cancer	3.91e-05	0.0007	CcSEcCtD
Ifosfamide—Hypotension—Etoposide—muscle cancer	3.89e-05	0.000696	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Methotrexate—muscle cancer	3.88e-05	0.000694	CcSEcCtD
Ifosfamide—Renal failure—Methotrexate—muscle cancer	3.84e-05	0.000688	CcSEcCtD
Ifosfamide—Stomatitis—Methotrexate—muscle cancer	3.81e-05	0.000682	CcSEcCtD
Ifosfamide—Conjunctivitis—Methotrexate—muscle cancer	3.8e-05	0.00068	CcSEcCtD
Ifosfamide—Hypersensitivity—Vincristine—muscle cancer	3.79e-05	0.000678	CcSEcCtD
Ifosfamide—Paraesthesia—Etoposide—muscle cancer	3.74e-05	0.000669	CcSEcCtD
Ifosfamide—Haematuria—Methotrexate—muscle cancer	3.73e-05	0.000667	CcSEcCtD
Ifosfamide—Pancreatitis—Doxorubicin—muscle cancer	3.72e-05	0.000666	CcSEcCtD
Ifosfamide—Dyspnoea—Etoposide—muscle cancer	3.71e-05	0.000664	CcSEcCtD
Ifosfamide—Somnolence—Etoposide—muscle cancer	3.7e-05	0.000662	CcSEcCtD
Ifosfamide—Angina pectoris—Doxorubicin—muscle cancer	3.7e-05	0.000662	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Methotrexate—muscle cancer	3.7e-05	0.000662	CcSEcCtD
Ifosfamide—Asthenia—Vincristine—muscle cancer	3.69e-05	0.00066	CcSEcCtD
Ifosfamide—Vomiting—Dactinomycin—muscle cancer	3.66e-05	0.000655	CcSEcCtD
Ifosfamide—Agranulocytosis—Methotrexate—muscle cancer	3.65e-05	0.000653	CcSEcCtD
Ifosfamide—Rash—Dactinomycin—muscle cancer	3.63e-05	0.000649	CcSEcCtD
Ifosfamide—Decreased appetite—Etoposide—muscle cancer	3.62e-05	0.000648	CcSEcCtD
Ifosfamide—Pancytopenia—Doxorubicin—muscle cancer	3.61e-05	0.000645	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Etoposide—muscle cancer	3.59e-05	0.000643	CcSEcCtD
Ifosfamide—Fatigue—Etoposide—muscle cancer	3.59e-05	0.000642	CcSEcCtD
Ifosfamide—Pain—Etoposide—muscle cancer	3.56e-05	0.000637	CcSEcCtD
Ifosfamide—Constipation—Etoposide—muscle cancer	3.56e-05	0.000637	CcSEcCtD
Ifosfamide—Dysuria—Doxorubicin—muscle cancer	3.55e-05	0.000635	CcSEcCtD
Ifosfamide—Haemoglobin—Methotrexate—muscle cancer	3.53e-05	0.000631	CcSEcCtD
Ifosfamide—Diarrhoea—Vincristine—muscle cancer	3.52e-05	0.000629	CcSEcCtD
Ifosfamide—Haemorrhage—Methotrexate—muscle cancer	3.51e-05	0.000628	CcSEcCtD
Ifosfamide—Hepatitis—Methotrexate—muscle cancer	3.51e-05	0.000628	CcSEcCtD
Ifosfamide—Pollakiuria—Doxorubicin—muscle cancer	3.51e-05	0.000628	CcSEcCtD
Ifosfamide—Urinary tract disorder—Methotrexate—muscle cancer	3.47e-05	0.00062	CcSEcCtD
Ifosfamide—Urethral disorder—Methotrexate—muscle cancer	3.44e-05	0.000616	CcSEcCtD
Ifosfamide—Feeling abnormal—Etoposide—muscle cancer	3.43e-05	0.000614	CcSEcCtD
Ifosfamide—Hyperglycaemia—Doxorubicin—muscle cancer	3.42e-05	0.000613	CcSEcCtD
Ifosfamide—Nausea—Dactinomycin—muscle cancer	3.42e-05	0.000612	CcSEcCtD
Ifosfamide—Pneumonia—Doxorubicin—muscle cancer	3.4e-05	0.000609	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Etoposide—muscle cancer	3.4e-05	0.000609	CcSEcCtD
Ifosfamide—Dizziness—Vincristine—muscle cancer	3.4e-05	0.000608	CcSEcCtD
Ifosfamide—Infestation NOS—Doxorubicin—muscle cancer	3.38e-05	0.000606	CcSEcCtD
Ifosfamide—Infestation—Doxorubicin—muscle cancer	3.38e-05	0.000606	CcSEcCtD
Ifosfamide—Visual impairment—Methotrexate—muscle cancer	3.38e-05	0.000605	CcSEcCtD
Ifosfamide—Stevens-Johnson syndrome—Doxorubicin—muscle cancer	3.36e-05	0.000601	CcSEcCtD
Ifosfamide—Renal failure—Doxorubicin—muscle cancer	3.33e-05	0.000596	CcSEcCtD
Ifosfamide—Erythema multiforme—Methotrexate—muscle cancer	3.32e-05	0.000594	CcSEcCtD
Ifosfamide—Neuropathy peripheral—Doxorubicin—muscle cancer	3.32e-05	0.000594	CcSEcCtD
Ifosfamide—Urticaria—Etoposide—muscle cancer	3.31e-05	0.000592	CcSEcCtD
Ifosfamide—Stomatitis—Doxorubicin—muscle cancer	3.3e-05	0.000591	CcSEcCtD
Ifosfamide—Abdominal pain—Etoposide—muscle cancer	3.29e-05	0.000589	CcSEcCtD
Ifosfamide—Body temperature increased—Etoposide—muscle cancer	3.29e-05	0.000589	CcSEcCtD
Ifosfamide—Conjunctivitis—Doxorubicin—muscle cancer	3.29e-05	0.000589	CcSEcCtD
Ifosfamide—Eye disorder—Methotrexate—muscle cancer	3.28e-05	0.000587	CcSEcCtD
Ifosfamide—Tinnitus—Methotrexate—muscle cancer	3.27e-05	0.000586	CcSEcCtD
Ifosfamide—Vomiting—Vincristine—muscle cancer	3.27e-05	0.000585	CcSEcCtD
Ifosfamide—Cardiac disorder—Methotrexate—muscle cancer	3.26e-05	0.000583	CcSEcCtD
Ifosfamide—Rash—Vincristine—muscle cancer	3.24e-05	0.00058	CcSEcCtD
Ifosfamide—Dermatitis—Vincristine—muscle cancer	3.24e-05	0.000579	CcSEcCtD
Ifosfamide—Haematuria—Doxorubicin—muscle cancer	3.23e-05	0.000578	CcSEcCtD
Ifosfamide—Hepatobiliary disease—Doxorubicin—muscle cancer	3.2e-05	0.000573	CcSEcCtD
Ifosfamide—Angiopathy—Methotrexate—muscle cancer	3.18e-05	0.00057	CcSEcCtD
Ifosfamide—Immune system disorder—Methotrexate—muscle cancer	3.17e-05	0.000567	CcSEcCtD
Ifosfamide—Mediastinal disorder—Methotrexate—muscle cancer	3.16e-05	0.000566	CcSEcCtD
Ifosfamide—Agranulocytosis—Doxorubicin—muscle cancer	3.16e-05	0.000565	CcSEcCtD
Ifosfamide—Chills—Methotrexate—muscle cancer	3.15e-05	0.000564	CcSEcCtD
Ifosfamide—Alopecia—Methotrexate—muscle cancer	3.1e-05	0.000555	CcSEcCtD
Ifosfamide—Bradycardia—Doxorubicin—muscle cancer	3.09e-05	0.000554	CcSEcCtD
Ifosfamide—Mental disorder—Methotrexate—muscle cancer	3.07e-05	0.00055	CcSEcCtD
Ifosfamide—Hypersensitivity—Etoposide—muscle cancer	3.07e-05	0.000549	CcSEcCtD
Ifosfamide—Erythema—Methotrexate—muscle cancer	3.05e-05	0.000547	CcSEcCtD
Ifosfamide—Malnutrition—Methotrexate—muscle cancer	3.05e-05	0.000547	CcSEcCtD
Ifosfamide—Haemoglobin—Doxorubicin—muscle cancer	3.05e-05	0.000547	CcSEcCtD
Ifosfamide—Nausea—Vincristine—muscle cancer	3.05e-05	0.000546	CcSEcCtD
Ifosfamide—Haemorrhage—Doxorubicin—muscle cancer	3.04e-05	0.000544	CcSEcCtD
Ifosfamide—Hepatitis—Doxorubicin—muscle cancer	3.04e-05	0.000544	CcSEcCtD
Ifosfamide—Urinary tract disorder—Doxorubicin—muscle cancer	3e-05	0.000537	CcSEcCtD
Ifosfamide—Asthenia—Etoposide—muscle cancer	2.99e-05	0.000535	CcSEcCtD
Ifosfamide—Connective tissue disorder—Doxorubicin—muscle cancer	2.99e-05	0.000535	CcSEcCtD
Ifosfamide—Urethral disorder—Doxorubicin—muscle cancer	2.98e-05	0.000533	CcSEcCtD
Ifosfamide—Pruritus—Etoposide—muscle cancer	2.94e-05	0.000527	CcSEcCtD
Ifosfamide—Visual impairment—Doxorubicin—muscle cancer	2.93e-05	0.000524	CcSEcCtD
Ifosfamide—Vision blurred—Methotrexate—muscle cancer	2.88e-05	0.000515	CcSEcCtD
Ifosfamide—Erythema multiforme—Doxorubicin—muscle cancer	2.87e-05	0.000514	CcSEcCtD
Ifosfamide—Diarrhoea—Etoposide—muscle cancer	2.85e-05	0.00051	CcSEcCtD
Ifosfamide—Eye disorder—Doxorubicin—muscle cancer	2.84e-05	0.000508	CcSEcCtD
Ifosfamide—Ill-defined disorder—Methotrexate—muscle cancer	2.83e-05	0.000507	CcSEcCtD
Ifosfamide—Tinnitus—Doxorubicin—muscle cancer	2.83e-05	0.000507	CcSEcCtD
Ifosfamide—Anaemia—Methotrexate—muscle cancer	2.82e-05	0.000505	CcSEcCtD
Ifosfamide—Flushing—Doxorubicin—muscle cancer	2.82e-05	0.000505	CcSEcCtD
Ifosfamide—Cardiac disorder—Doxorubicin—muscle cancer	2.82e-05	0.000505	CcSEcCtD
Ifosfamide—Angiopathy—Doxorubicin—muscle cancer	2.76e-05	0.000494	CcSEcCtD
Ifosfamide—Malaise—Methotrexate—muscle cancer	2.75e-05	0.000493	CcSEcCtD
Ifosfamide—Dizziness—Etoposide—muscle cancer	2.75e-05	0.000493	CcSEcCtD
Ifosfamide—Immune system disorder—Doxorubicin—muscle cancer	2.74e-05	0.000491	CcSEcCtD
Ifosfamide—Vertigo—Methotrexate—muscle cancer	2.74e-05	0.000491	CcSEcCtD
Ifosfamide—Mediastinal disorder—Doxorubicin—muscle cancer	2.74e-05	0.00049	CcSEcCtD
Ifosfamide—Leukopenia—Methotrexate—muscle cancer	2.73e-05	0.00049	CcSEcCtD
Ifosfamide—Chills—Doxorubicin—muscle cancer	2.73e-05	0.000488	CcSEcCtD
Ifosfamide—Arrhythmia—Doxorubicin—muscle cancer	2.71e-05	0.000486	CcSEcCtD
Ifosfamide—Alopecia—Doxorubicin—muscle cancer	2.68e-05	0.000481	CcSEcCtD
Ifosfamide—Cough—Methotrexate—muscle cancer	2.67e-05	0.000477	CcSEcCtD
Ifosfamide—Mental disorder—Doxorubicin—muscle cancer	2.66e-05	0.000477	CcSEcCtD
Ifosfamide—Convulsion—Methotrexate—muscle cancer	2.65e-05	0.000474	CcSEcCtD
Ifosfamide—Vomiting—Etoposide—muscle cancer	2.65e-05	0.000474	CcSEcCtD
Ifosfamide—Malnutrition—Doxorubicin—muscle cancer	2.65e-05	0.000474	CcSEcCtD
Ifosfamide—Erythema—Doxorubicin—muscle cancer	2.65e-05	0.000474	CcSEcCtD
Ifosfamide—Rash—Etoposide—muscle cancer	2.62e-05	0.00047	CcSEcCtD
Ifosfamide—Dermatitis—Etoposide—muscle cancer	2.62e-05	0.000469	CcSEcCtD
Ifosfamide—Chest pain—Methotrexate—muscle cancer	2.6e-05	0.000466	CcSEcCtD
Ifosfamide—Arthralgia—Methotrexate—muscle cancer	2.6e-05	0.000466	CcSEcCtD
Ifosfamide—Myalgia—Methotrexate—muscle cancer	2.6e-05	0.000466	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	2.58e-05	0.000462	CcSEcCtD
Ifosfamide—Discomfort—Methotrexate—muscle cancer	2.57e-05	0.00046	CcSEcCtD
Ifosfamide—Confusional state—Methotrexate—muscle cancer	2.51e-05	0.00045	CcSEcCtD
Ifosfamide—Anaphylactic shock—Methotrexate—muscle cancer	2.49e-05	0.000446	CcSEcCtD
Ifosfamide—Vision blurred—Doxorubicin—muscle cancer	2.49e-05	0.000446	CcSEcCtD
Ifosfamide—Infection—Methotrexate—muscle cancer	2.48e-05	0.000443	CcSEcCtD
Ifosfamide—Nausea—Etoposide—muscle cancer	2.47e-05	0.000443	CcSEcCtD
Ifosfamide—Ill-defined disorder—Doxorubicin—muscle cancer	2.45e-05	0.000439	CcSEcCtD
Ifosfamide—Nervous system disorder—Methotrexate—muscle cancer	2.44e-05	0.000438	CcSEcCtD
Ifosfamide—Anaemia—Doxorubicin—muscle cancer	2.44e-05	0.000438	CcSEcCtD
Ifosfamide—Thrombocytopenia—Methotrexate—muscle cancer	2.44e-05	0.000437	CcSEcCtD
Ifosfamide—Agitation—Doxorubicin—muscle cancer	2.43e-05	0.000435	CcSEcCtD
Ifosfamide—Skin disorder—Methotrexate—muscle cancer	2.42e-05	0.000434	CcSEcCtD
Ifosfamide—Hyperhidrosis—Methotrexate—muscle cancer	2.41e-05	0.000431	CcSEcCtD
Ifosfamide—Malaise—Doxorubicin—muscle cancer	2.39e-05	0.000427	CcSEcCtD
Ifosfamide—Vertigo—Doxorubicin—muscle cancer	2.38e-05	0.000425	CcSEcCtD
Ifosfamide—Anorexia—Methotrexate—muscle cancer	2.38e-05	0.000425	CcSEcCtD
Ifosfamide—Leukopenia—Doxorubicin—muscle cancer	2.37e-05	0.000424	CcSEcCtD
Ifosfamide—Palpitations—Doxorubicin—muscle cancer	2.34e-05	0.000418	CcSEcCtD
Ifosfamide—Hypotension—Methotrexate—muscle cancer	2.33e-05	0.000417	CcSEcCtD
Ifosfamide—Cough—Doxorubicin—muscle cancer	2.31e-05	0.000413	CcSEcCtD
Ifosfamide—Convulsion—Doxorubicin—muscle cancer	2.29e-05	0.00041	CcSEcCtD
Ifosfamide—Hypertension—Doxorubicin—muscle cancer	2.28e-05	0.000409	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Methotrexate—muscle cancer	2.27e-05	0.000407	CcSEcCtD
Ifosfamide—Arthralgia—Doxorubicin—muscle cancer	2.25e-05	0.000403	CcSEcCtD
Ifosfamide—Chest pain—Doxorubicin—muscle cancer	2.25e-05	0.000403	CcSEcCtD
Ifosfamide—Myalgia—Doxorubicin—muscle cancer	2.25e-05	0.000403	CcSEcCtD
Ifosfamide—Paraesthesia—Methotrexate—muscle cancer	2.24e-05	0.000401	CcSEcCtD
Ifosfamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	2.24e-05	0.0004	CcSEcCtD
Ifosfamide—Discomfort—Doxorubicin—muscle cancer	2.22e-05	0.000398	CcSEcCtD
Ifosfamide—Dyspnoea—Methotrexate—muscle cancer	2.22e-05	0.000398	CcSEcCtD
Ifosfamide—Somnolence—Methotrexate—muscle cancer	2.22e-05	0.000397	CcSEcCtD
Ifosfamide—Confusional state—Doxorubicin—muscle cancer	2.18e-05	0.00039	CcSEcCtD
Ifosfamide—Decreased appetite—Methotrexate—muscle cancer	2.17e-05	0.000388	CcSEcCtD
Ifosfamide—Oedema—Doxorubicin—muscle cancer	2.16e-05	0.000386	CcSEcCtD
Ifosfamide—Anaphylactic shock—Doxorubicin—muscle cancer	2.16e-05	0.000386	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Methotrexate—muscle cancer	2.15e-05	0.000385	CcSEcCtD
Ifosfamide—Fatigue—Methotrexate—muscle cancer	2.15e-05	0.000385	CcSEcCtD
Ifosfamide—Infection—Doxorubicin—muscle cancer	2.14e-05	0.000384	CcSEcCtD
Ifosfamide—Pain—Methotrexate—muscle cancer	2.13e-05	0.000382	CcSEcCtD
Ifosfamide—Nervous system disorder—Doxorubicin—muscle cancer	2.12e-05	0.000379	CcSEcCtD
Ifosfamide—Thrombocytopenia—Doxorubicin—muscle cancer	2.11e-05	0.000378	CcSEcCtD
Ifosfamide—Skin disorder—Doxorubicin—muscle cancer	2.1e-05	0.000375	CcSEcCtD
Ifosfamide—Hyperhidrosis—Doxorubicin—muscle cancer	2.09e-05	0.000374	CcSEcCtD
Ifosfamide—Anorexia—Doxorubicin—muscle cancer	2.06e-05	0.000368	CcSEcCtD
Ifosfamide—Feeling abnormal—Methotrexate—muscle cancer	2.05e-05	0.000368	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Methotrexate—muscle cancer	2.04e-05	0.000365	CcSEcCtD
Ifosfamide—Hypotension—Doxorubicin—muscle cancer	2.02e-05	0.000361	CcSEcCtD
Ifosfamide—Urticaria—Methotrexate—muscle cancer	1.98e-05	0.000355	CcSEcCtD
Ifosfamide—Abdominal pain—Methotrexate—muscle cancer	1.97e-05	0.000353	CcSEcCtD
Ifosfamide—Body temperature increased—Methotrexate—muscle cancer	1.97e-05	0.000353	CcSEcCtD
Ifosfamide—Musculoskeletal discomfort—Doxorubicin—muscle cancer	1.97e-05	0.000352	CcSEcCtD
Ifosfamide—Paraesthesia—Doxorubicin—muscle cancer	1.94e-05	0.000347	CcSEcCtD
Ifosfamide—Dyspnoea—Doxorubicin—muscle cancer	1.92e-05	0.000345	CcSEcCtD
Ifosfamide—Somnolence—Doxorubicin—muscle cancer	1.92e-05	0.000344	CcSEcCtD
Ifosfamide—Decreased appetite—Doxorubicin—muscle cancer	1.88e-05	0.000336	CcSEcCtD
Ifosfamide—Gastrointestinal disorder—Doxorubicin—muscle cancer	1.86e-05	0.000334	CcSEcCtD
Ifosfamide—Fatigue—Doxorubicin—muscle cancer	1.86e-05	0.000333	CcSEcCtD
Ifosfamide—Constipation—Doxorubicin—muscle cancer	1.85e-05	0.00033	CcSEcCtD
Ifosfamide—Pain—Doxorubicin—muscle cancer	1.85e-05	0.00033	CcSEcCtD
Ifosfamide—Hypersensitivity—Methotrexate—muscle cancer	1.84e-05	0.000329	CcSEcCtD
Ifosfamide—Asthenia—Methotrexate—muscle cancer	1.79e-05	0.00032	CcSEcCtD
Ifosfamide—Feeling abnormal—Doxorubicin—muscle cancer	1.78e-05	0.000318	CcSEcCtD
Ifosfamide—Gastrointestinal pain—Doxorubicin—muscle cancer	1.77e-05	0.000316	CcSEcCtD
Ifosfamide—Pruritus—Methotrexate—muscle cancer	1.76e-05	0.000316	CcSEcCtD
Ifosfamide—Urticaria—Doxorubicin—muscle cancer	1.71e-05	0.000307	CcSEcCtD
Ifosfamide—Abdominal pain—Doxorubicin—muscle cancer	1.71e-05	0.000306	CcSEcCtD
Ifosfamide—Body temperature increased—Doxorubicin—muscle cancer	1.71e-05	0.000306	CcSEcCtD
Ifosfamide—Diarrhoea—Methotrexate—muscle cancer	1.71e-05	0.000305	CcSEcCtD
Ifosfamide—Dizziness—Methotrexate—muscle cancer	1.65e-05	0.000295	CcSEcCtD
Ifosfamide—Hypersensitivity—Doxorubicin—muscle cancer	1.59e-05	0.000285	CcSEcCtD
Ifosfamide—Vomiting—Methotrexate—muscle cancer	1.59e-05	0.000284	CcSEcCtD
Ifosfamide—Rash—Methotrexate—muscle cancer	1.57e-05	0.000281	CcSEcCtD
Ifosfamide—Dermatitis—Methotrexate—muscle cancer	1.57e-05	0.000281	CcSEcCtD
Ifosfamide—Asthenia—Doxorubicin—muscle cancer	1.55e-05	0.000277	CcSEcCtD
Ifosfamide—Pruritus—Doxorubicin—muscle cancer	1.53e-05	0.000273	CcSEcCtD
Ifosfamide—Nausea—Methotrexate—muscle cancer	1.48e-05	0.000265	CcSEcCtD
Ifosfamide—Diarrhoea—Doxorubicin—muscle cancer	1.48e-05	0.000264	CcSEcCtD
Ifosfamide—Dizziness—Doxorubicin—muscle cancer	1.43e-05	0.000256	CcSEcCtD
Ifosfamide—Vomiting—Doxorubicin—muscle cancer	1.37e-05	0.000246	CcSEcCtD
Ifosfamide—Rash—Doxorubicin—muscle cancer	1.36e-05	0.000244	CcSEcCtD
Ifosfamide—Dermatitis—Doxorubicin—muscle cancer	1.36e-05	0.000243	CcSEcCtD
Ifosfamide—Nausea—Doxorubicin—muscle cancer	1.28e-05	0.00023	CcSEcCtD
